Ignite Creation Date:
2025-12-25 @ 3:47 AM
Ignite Modification Date:
2025-12-26 @ 2:34 AM
Study NCT ID:
NCT04633902
Status:
UNKNOWN
Last Update Posted:
2022-12-06
First Post:
2020-11-12
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation
Sponsor:
California Pacific Medical Center Research Institute
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-03-03
Start Date Type:
ACTUAL
Primary Completion Date:
2023-06-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2024-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2020-11-12
First Submit QC Date:
None
Study First Post Date:
2020-11-18
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-12-02
Last Update Post Date:
2022-12-06
Last Update Post Date Type:
ACTUAL